BrightGene Bio-Medical Technology Balance Sheet Health
Financial Health criteria checks 2/6
BrightGene Bio-Medical Technology has a total shareholder equity of CN¥2.3B and total debt of CN¥2.1B, which brings its debt-to-equity ratio to 91.3%. Its total assets and total liabilities are CN¥4.9B and CN¥2.5B respectively. BrightGene Bio-Medical Technology's EBIT is CN¥178.6M making its interest coverage ratio 5.2. It has cash and short-term investments of CN¥505.4M.
Key information
91.3%
Debt to equity ratio
CN¥2.14b
Debt
| Interest coverage ratio | 5.2x |
| Cash | CN¥505.36m |
| Equity | CN¥2.34b |
| Total liabilities | CN¥2.54b |
| Total assets | CN¥4.88b |
Recent financial health updates
Recent updates
BrightGene Bio-Medical Technology Co., Ltd.'s (SHSE:688166) 28% Price Boost Is Out Of Tune With Earnings
Oct 01
Is BrightGene Bio-Medical Technology (SHSE:688166) Using Too Much Debt?
Sep 19Some BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) Shareholders Look For Exit As Shares Take 29% Pounding
Aug 01BrightGene Bio-Medical Technology Co., Ltd.'s (SHSE:688166) 47% Share Price Surge Not Quite Adding Up
May 21BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected
Mar 01Financial Position Analysis
Short Term Liabilities: 688166's short term assets (CN¥1.4B) exceed its short term liabilities (CN¥885.5M).
Long Term Liabilities: 688166's short term assets (CN¥1.4B) do not cover its long term liabilities (CN¥1.7B).
Debt to Equity History and Analysis
Debt Level: 688166's net debt to equity ratio (69.7%) is considered high.
Reducing Debt: 688166's debt to equity ratio has increased from 0% to 91.3% over the past 5 years.
Debt Coverage: 688166's debt is not well covered by operating cash flow (10.1%).
Interest Coverage: 688166's interest payments on its debt are well covered by EBIT (5.2x coverage).